The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL		
MB Number:	3235-0076	
stimated average burd	len	
oure per recommen:	4.00	

1. Issuer's Identity			
CIK (Filer ID Number)	Previous Names	X None	Entity Type
0001539029			X Corporation
Name of Issuer			Limited Partnership
Clearside Biomedical, Inc.			Limited Liability Company
Jurisdiction of Incorporation/Organ	nization		General Partnership
DELAWARE			
Year of Incorporation/Organization	1		Business Trust
Over Five Years Ago			Other (Specify)
X Within Last Five Years (Speci	fy Year) 2011		
Yet to Be Formed			
2. Principal Place of Business a	nd Contact Information		
Name of Issuer			
Clearside Biomedical, Inc.			
Street Address 1		Street Address 2	
212 RIVERGATE DRIVE			
	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
SUWANEE (GEORGIA	30024	678-428-7570
3. Related Persons			
Last Name	First Name		Middle Name
White	Daniel		H.
Street Address 1	Street Address 2		
212 Rivergate Drive			
City	State/Province/Co	untry	ZIP/PostalCode
Suwanee	GEORGIA		30024
Relationship: X Executive Office	r Director Promoter		
Clarification of Response (if Neces	ssary):		
	5		
Last Name	First Name		Middle Name
Prausnitz Street Address 1	Mark Street Address 2		
School of Chemical Engineering, GA		X /	
City	State/Province/Co		ZIP/PostalCode
Atlanta	GEORGIA	on iti y	30332-0100
Relationship: Executive Office			3332 0100
· <u>L</u>			
Clarification of Response (if Neces	ssary):		
Last Name	First Name		Middle Name
Shaffer	Christy		
Street Address 1	Street Address 2		
280 South Mangum Street	Suite 350		

City	State/Province/Country	ZIP/PostalCode	
Durham	NORTH CAROLINA	27701	
Relationship: Executive Officer X Director Promoter			
Clarification of Response (if Necessary):			
Last Name	First Name	Middle Name	
Thorp	Clay		
Street Address 1 280 South Mangum Street	Street Address 2 Suite 350		
City	State/Province/Country	ZIP/PostalCode	
Durham	NORTH CAROLINA	27701	
Relationship: Executive Officer X Direct	ctor Promoter		
Clarification of Response (if Necessary):			
4. Industry Group			
Agriculture	Health Care	Retailing	
Banking & Financial Services	Biotechnology		
Commercial Banking		Restaurants	
Insurance	Health Insurance	Technology	
Investing	Hospitals & Physicians	Computers	
Investment Banking	X Pharmaceuticals	Telecommunications	
Pooled Investment Fund	Other Health Care	Other Technology	
Is the issuer registered as	Manufacturing	Travel	
an investment company under	Real Estate	Airlines & Airports	
the Investment Company Act of 1940?	Commercial		
Yes No		Lodging & Conventions	
	Construction	Tourism & Travel Services	
Other Banking & Financial Services	REITS & Finance	Other Travel	
Business Services	Residential		
Energy	Other Real Estate	Other	
Coal Mining	Other Real Estate		
Electric Utilities			
Energy Conservation			
Environmental Services			
Oil & Gas			
Other Energy			
5. Issuer Size			
Revenue Range OR	Aggregate Net Asset Va	alue Range	
No Revenues	No Aggregate Net As		
\$1 - \$1,000,000	\$1 - \$5,000,000		
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,000	0,000	
\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,00		
\$25,000,001 -	\$50,000,001 - \$100,0		
\$100,000,000			
Over \$100,000,000	Over \$100,000,000		
X Decline to Disclose	Decline to Disclose		

Not Applicable	Not Applicable
6. Federal Exemption(s) and Exclusion(s) Claim	ed (select all that apply)
	Rule 505
Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i)	X Rule 506
Rule 504 (b)(1)(ii)	Securities Act Section 4(5)
Rule 504 (b)(1)(iii)	Investment Company Act Section 3(c)
	Section 3(c)(1) Section 3(c)(9)
	Section 3(c)(2) Section 3(c)(10)
	Section 3(c)(3) Section 3(c)(11)
	Section 3(c)(4) Section 3(c)(12)
	Section 3(c)(5) Section 3(c)(13)
	Section 3(c)(6) Section 3(c)(14)
	Section 3(c)(7)
7. Type of Filing	
	First Sale Yet to Occur
Amendment	
8. Duration of Offering	
Does the Issuer intend this offering to last more that	an one year? Yes X No
Does the issuel litteria this offering to last more the	Trone year: Tes A No
9. Type(s) of Securities Offered (select all that ap	ply)
X Equity	Pooled Investment Fund Interests
Debt	Tenant-in-Common Securities
Option, Warrant or Other Right to Acquire Anoth	
Security to be Acquired Upon Exercise of Optio	n Warrant or Other
Right to Acquire Security	Other (describe)
10. Business Combination Transaction	
Is this offering being made in connection with a bus	siness combination transaction, such as a
merger, acquisition or exchange offer?	Yes X No
Clarification of Response (if Necessary):	
11. Minimum Investment	
Minimum investment accepted from any outside in	vestor \$50,000 USD
12. Sales Compensation	
Recipient	Recipient CRD Number X None
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number X None
Street Address 1	Street Address 2
City	State/Province/Country ZIP/Postal Code
State(s) of Solicitation (soloct all that apply)	<i>,</i>
Check "All States" or check individual States	Il States Foreign/non-US
13. Offering and Sales Amounts	
Total Offering Amount \$4,000,000 USD or	Indefinite
Total Amount Sold \$1,200,692 USD	
. , , , , , , , , , , , , , , , , , , ,	

Total Remaining to be Sold \$2,799,308 USD or Indefinite	
Clarification of Response (if Necessary):	
14. Investors	
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.	
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:	
15. Sales Commissions & Finder's Fees Expenses	
Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not kn estimate and check the box next to the amount.	own, provide an
Sales Commissions \$0 USD Estimate	
Finders' Fees \$0 USD Estimate	
Clarification of Response (if Necessary):	
16. Use of Proceeds	
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the perso be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate box next to the amount.	
\$500,000 USD X Estimate	
Clarification of Response (if Necessary):	
Signature and Submission	
Places varify the information you have entered and review the Torms of Submission below before signing and clicking SI	IRMIT bolow to

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Clearside Biomedical, Inc.	Daniel H. White	Daniel H. White	President	2012-01-09

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

^{*} This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.